Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
70 studies found for:    SGN-35
Show Display Options
Rank Status Study
1 Active, not recruiting SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
Conditions: CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma;   Lymphoma, Primary Cutaneous Anaplastic Large Cell;   Lymphomatoid Papulosis;   Mycosis Fungoides;   Skin Lymphoma;   Cutaneous Lymphomas;   Lymphoma;   Hematologic Disorder
Intervention: Drug: SGN-35
2 Terminated A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Interventions: Drug: SGN-35;   Drug: gemcitabine
3 Completed Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies
Conditions: Lymphoma, Non-Hodgkin;   Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic
Intervention: Drug: SGN-35
4 Completed Cardiac Safety Study of Brentuximab Vedotin (SGN-35)
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin
5 Active, not recruiting Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin's Lymphoma
Interventions: Drug: brentuximab vedotin (SGN-35);   Drug: Brentuximab Vedotin (SGN-35)
6 Active, not recruiting
Has Results
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
Condition: Disease, Hodgkin
Interventions: Drug: brentuximab vedotin;   Drug: placebo
7 Active, not recruiting A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Conditions: Primary Cutaneous Anaplastic Large Cell Lymphoma,;   Mycosis Fungoides;   Cutaneous T-Cell Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Methotrexate or Bexarotene
8 Recruiting Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Condition: Hodgkin Lymphoma
Intervention: Drug: Mocetinostat Plus Brentuximab Vedotin
9 Completed
Has Results
A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma
Conditions: Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin
10 Completed Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
Conditions: Carcinomas;   Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin;   Neoplasms
Interventions: Drug: brentuximab vedotin;   Drug: rifampin;   Drug: midazolam;   Drug: ketoconazole
11 Completed A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL
Condition: Primary Mediastinal Large B-cell Lymphoma.
Intervention: Drug: Brentuximab Vedotin
12 Active, not recruiting Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level
Conditions: Lymphoma, Non-Hodgkin;   Cutaneous Lymphoma;   Cutaneous T Cell Lymphoma;   Mycosis Fungoides;   Sezary Syndrome
Intervention: Drug: Brentuximab vedotin
13 Active, not recruiting Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors
Condition: Germ Cell Cancer
Intervention: Drug: Brentuximab Vedotin
14 Available A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin;   Lymphoma, T-Cell, Cutaneous
Intervention: Drug: brentuximab vedotin
15 Completed
Has Results
A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma
Condition: Disease, Hodgkin
Intervention: Drug: brentuximab vedotin
16 Recruiting A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma
Conditions: HIV Infection;   HIV-associated Hodgkin Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage IV Adult Hodgkin Lymphoma
Interventions: Drug: brentuximab vedotin;   Drug: Doxorubicin Hydrochloride;   Drug: Vinblastine;   Drug: Dacarbazine
17 Completed
Has Results
A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin
18 Active, not recruiting Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Conditions: Hodgkin Lymphoma;   Anaplastic Large-cell Lymphoma
Intervention: Drug: brentuximab vedotin
19 Active, not recruiting Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma
Condition: Hodgkin Lymphoma, Adult
Interventions: Drug: Brentuximab vedotin;   Drug: ABVD
20 Recruiting Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia
Conditions: Aggressive Systemic Mastocytosis;   Mast Cell Leukemia;   Systemic Mastocytosis
Intervention: Drug: brentuximab vedotin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.